High-dose rifapentine for treating tuberculosis during pregnancy
Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
This project looks at whether higher-dose rifapentine could be a shorter TB treatment option for pregnant and breastfeeding people, including those living with HIV.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11400225 on NIH RePORTER |
What this research studies
If you join, you will be shown different treatment scenarios and asked which options you or your healthcare provider would prefer, weighing factors like baby's safety, treatment length, side effects, and dosing. The team will use a discrete choice experiment (DCE) method to present hypothetical regimens and collect your choices and reasons. Participants will include pregnant and breastfeeding people in TB-affected regions and the healthcare providers who care for them, and responses will be analyzed to see which treatment features matter most. Results will help design safer dosing and inclusion strategies for future trials and treatment guidelines.
Who could benefit from this research
Good fit: Pregnant or breastfeeding people with current or recent tuberculosis, including those living with HIV, especially in high-TB-burden countries, are the ideal participants.
Not a fit: People who are not pregnant or breastfeeding, do not have TB, or who live outside the study regions are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could support safe use of a shorter, high-dose rifapentine TB regimen in pregnancy and breastfeeding, potentially reducing maternal and infant TB-related harm.
How similar studies have performed: Shorter rifapentine-based TB regimens have worked well in non-pregnant adults, but testing high-dose rifapentine and directly asking pregnant/breastfeeding people about treatment choices is relatively new.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Hirsch-Moverman, Yael R — Columbia University Health Sciences
- Study coordinator: Hirsch-Moverman, Yael R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.